1. <source id="c6bcq"><nav id="c6bcq"><strike id="c6bcq"></strike></nav></source>
      1. <rp id="c6bcq"><nav id="c6bcq"><button id="c6bcq"></button></nav></rp>
        <rt id="c6bcq"><nav id="c6bcq"><button id="c6bcq"></button></nav></rt>

        <rt id="c6bcq"><meter id="c6bcq"><button id="c6bcq"></button></meter></rt>
      2. A LONG-TERM FOCUS
        ON INNOVATION

        We welcome the opportunity to discuss:

        BUSINESS
        DEVELOPMENT
        COLLABORATIONS

        • In-licensing and / or R&D collaborations
          • Creative collaborations in emerging fields
          • Best-in-class technology platforms and capabilities to enhance the Regeneron antibody pipeline
        • Strategic late-stage development and commercial partnerships with other leading biopharma companies
        • Collaborations that maximize the global potential of our pipeline and ability to deliver new medicines to patients around the globe

        Introduce your assets or discuss
        late-stage partnership

        ACADEMIC &
        RESEARCH
        COLLABORATIONS

        • Non-Clinical Research Collaborations providing investigators from academic and research institutions access to our:

        Learn more

        • Clinical Collaborations / Investigator Initiated Studies (IIS) providing investigators and clinicians access to and / or funding for our:

        Learn more

        OUR BUSINESS DEVELOPMENT STRATEGY

        Our entrepreneurial culture and history as one of the industry’s longest-standing biotech companies fosters a high-science mindset, nimble decision-making and highly collaborative relationships.

        We follow the science, rather than limiting our innovations to any one therapeutic area. We are open to collaboration opportunities with the potential to offer important benefits to patients, representing a true scientific or medical advance. In particular, we consider:

        • Novel platforms that enable next-generation therapeutics
        • Technologies for antibody discovery and development against new / challenging targets
        • New approaches that enhance activity of tumor-directed antibodies
        • Biomarker discovery and validation
        • Drug delivery or formulation technologies that improve the efficacy / safety profile, address a CMC or supply challenge or enhance patient convenience or compliance
        • Studying the potential of combinations pairing our pipeline molecules with other innovative clinical-stage therapeutic candidates
        • Collaborations with leading academic groups to advance our efforts in human genetics, animal model development, target discovery, target validation and antibody discovery

        SOME OF OUR CURRENT COLLABORATORS INCLUDE:


        Bayer logo

        Global ophthalmology
        collaborations

        Sanofi logo

        Antibody and immunotherapy
        collaborations

        Icahn School of Medicine logo

        Antibody discovery
        agreement

        Columbia University logo

        Research collaboration on genetic
        basis of familial disease

        Teva logo

        Global collaboration for
        investigational pain therapeutic

        Intellia Therapeutics logo

        Gene-editing technology
        collaboration

        Adicet Bio logo

        Engineered immune cell
        therapeutics collaboration

        Alnylam logo

        RNA interference (RNAi)
        therapeutics collaboration

        紫夜影视网